Hyperion DeFi, Inc.
Hyperion DeFi, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arct… Read more
Hyperion DeFi, Inc. (HYPD) - Net Assets
Latest net assets as of September 2025: $70.76 Million USD
Based on the latest financial reports, Hyperion DeFi, Inc. (HYPD) has net assets worth $70.76 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($82.79 Million) and total liabilities ($12.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $70.76 Million |
| % of Total Assets | 85.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 106.06 |
Hyperion DeFi, Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Hyperion DeFi, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hyperion DeFi, Inc. (2020–2024)
The table below shows the annual net assets of Hyperion DeFi, Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-13.10 Million | -245.53% |
| 2023-12-31 | $9.00 Million | -47.78% |
| 2022-12-31 | $17.23 Million | -15.79% |
| 2021-12-31 | $20.47 Million | +33.73% |
| 2020-12-31 | $15.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hyperion DeFi, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11786907300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $151.00 | % |
| Other Components | $182.21 Million | % |
| Total Equity | $-13.10 Million | 100.00% |
Hyperion DeFi, Inc. Competitors by Market Cap
The table below lists competitors of Hyperion DeFi, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CCID Consulting Company Limited
F:CCX
|
$16.59 Million |
|
Skillsoft Corp.
NYSE:SKIL
|
$16.59 Million |
|
Daesung Eltec Co. Ltd
KQ:025440
|
$16.59 Million |
|
Sunfar Computer Co Ltd
TWO:6154
|
$16.59 Million |
|
FLANIGANS ENTER. DL-1
F:0DY
|
$16.58 Million |
|
Cohen & Company Inc
NYSE MKT:COHN
|
$16.58 Million |
|
Vanachai Group Public Company Limited
BK:VNG
|
$16.58 Million |
|
Dis-Chem Pharmacies
JSE:DCP
|
$16.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hyperion DeFi, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,999,094 to -13,095,952, a change of -22,095,046 (-245.5%).
- Net loss of 49,818,433 reduced equity.
- New share issuances of 25,619,417 increased equity.
- Other factors increased equity by 2,103,970.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-49.82 Million | -380.41% |
| Share Issuances | $25.62 Million | +195.63% |
| Other Changes | $2.10 Million | +16.07% |
| Total Change | $- | -245.53% |
Book Value vs Market Value Analysis
This analysis compares Hyperion DeFi, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $58.15 | $3.76 | x |
| 2021-12-31 | $62.20 | $3.76 | x |
| 2022-12-31 | $40.97 | $3.76 | x |
| 2023-12-31 | $17.55 | $3.76 | x |
| 2024-12-31 | $-15.72 | $3.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hyperion DeFi, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -86888.57%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-131.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -129.18% | -988.49% | 0.06x | 2.22x | $-21.30 Million |
| 2021 | -62.44% | -91.27% | 0.44x | 1.55x | $-14.83 Million |
| 2022 | -162.53% | 0.00% | 0.00x | 1.80x | $-29.73 Million |
| 2023 | -302.93% | -719859.94% | 0.00x | 3.20x | $-28.16 Million |
| 2024 | 0.00% | -86888.57% | 0.02x | 0.00x | $-48.51 Million |
Industry Comparison
This section compares Hyperion DeFi, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hyperion DeFi, Inc. (HYPD) | $70.76 Million | -129.18% | 0.17x | $16.59 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |